Catalogue of Services
What do LS RIs offer the life science community?
The 13 European Life Science Research Infrastructures (LS RIs) have the mission to support cutting-edge science by offering access to their resources and services to European scientists from academia and industry.
Resources and services can simply be consultation, access to experts, but also access to data and biological samples, use of data analysis tools, access to facilities (e.g. highly specialised microscopes) plus support from technicians and much more.
Some of these services are even free to use for institutions location in the RI's member states.
The Catalogue of Services, which has been developed within the CORBEL project, is the first tool to list the main services of all LS RIs at a glance and it aims to facilitate the utilisation of RI services by researchers from all over the world. The Catalogue of Services as displayed below aims to provide you a basic overview on existing services within distinct thematic fields.
You can either use the Catalogue of Services to identify a single RI to help you with your work or you can create a service pipeline, i.e. using several RIs simultaneously.
What’s your need?
Data & Databases
Technologies & Facilities
- accreditated/certified facilities (ISO certified, GLP, GMP, GCP)
- adaptation / development of assays (compounds etc.)
- adaptation / development of assays (human/non-human samples)
- high-throughput screening
- imaging (biological)
- imaging (medical)
- isolation / cultivation / characterisation of microorganisms
- -omics technology platforms
- plant phenotyping technologies/facilities
- production of high quality protein samples
- structural biology technologies/software
Models & Tools
Expertise & Support
- biomarker validation
- biosecurity / biosafety (incl. regulatory) issues
- data management expertise
- development of project towards a medical application
- ethical / legal issues, informed consent
- innovation management support
- mouse model generation, phenotyping and cryopreservation
- multinational clinical trial (establishment / management / monitoring)
- outbreak / emergency response / epidemiology
- support to submit a project proposal
- systems biology expertise
- training courses
- The following RIs offer complementary services:
BBMRI-ERIC is a research infrastructure of biobanks and biomolecular resources. Our main goal is to provide expertise and services, advancing the use of European sample collections and its data for the benefit of human health. Our activities are on a non-economic basis and primarily intended for our member countries.
Why work with us
Members: AT, BE, BG, CZ, EE, FI, DE, GR, IT, LT, ML, NL, NO, PL, SE, UK
Observer: IARC/WHO, CY, TR, CH
BBMRI-ERIC aims to improve the accessibility and interoperability of the existing comprehensive collections, either population-based or clinical-oriented, of biological samples from different (sub-) populations of Europe or rare diseases. These collections include the attached data on factors such as health status, nutrition, lifestyle, and environmental exposure of the study subjects. In order to fully realize the enormous potential of European biobanks and biomolecular resources for the benefit of European citizens, clinical, ethical and legal experts, the biotech and pharmaceutical industry, patient advocacy groups are collaborating in a participatory governance model (Stakeholder's Forum). The aim is to achieve standards and guidelines that properly balance individual values, such as protection of privacy and informed consent, with shared values of facilitated access to progress in health care and disease prevention.
BBMRI-ERIC will increase efficacy and excellence of European bio-medical research by facilitating fair access to quality-defined human health/disease-relevant biological resources through the inclusion of associated data in an efficient and ethically and legally compliant manner; by reducing the fragmentation of the bio-medical research landscape through harmonisation of procedures, implementation of common standards and fostering high-level collaboration; and by capacity-building in countries with less developed biobanking communities thereby contributing to Europe's cohesion policy and strengthening the ERA.
The EU’s ageing population is resulting in an increase in many of those diseases and consequently an increased healthcare expenditure for senior citizens that place pressure on the sustainability and viability of the EU’s healthcare systems. Through BBMRI-ERIC, biobanks and biomolecular resources shall develop into one of the most important tools for biomedical and clinical discovery. New medical applications, new therapies, new preventive techniques, new diagnostics, personalised or stratified medicine, and new biomedical industries shall evolve to improve socio-economic competitiveness and increase possibilities for equitable healthcare in Europe. The anticipated development shall pave the way for a new research culture in Europe. Expectantly, BBMRI-ERIC will have an impact on partnerships with patients/donors, who know that their own tissues, samples and personal data can yield discoveries and advances in medicine, diagnostics, and therapies. In return, BBMRI-ERIC is taking up the responsibility to make sure that the samples and data that have been entrusted for research are used in the best way possible for the advancement of knowledge, ultimately contributing to improved health care.
The key benefits for users of BBMRI-ERIC are fair access to quality-controlled samples and/or data from population-based, disease-oriented or rare disease biobanks including expertise in handling these biological resources for scientific purposes (ethical, legal and societal issues as well as quality handling). BBMRI-ERIC connects a distributed research infrastructure of biobanks and biomolecular resources for the benefit of the users of such resources. It puts pan-European biobanks on the map and promotes their specific strengths. BBMRI increases the accessibility to quality controlled human biological samples and associated biomedical and biomolecular data in making them findable, accessible, interoperable and reusable. Ultimately, this is key for advancing stratified and precision medicine.
Contact person(s): Anne-Charlotte Fauvel
EATRIS supports researchers in translating their findings into novel interventions including preventive, diagnostic or therapeutic products up to clinical proof of concept. The infrastructure comprises over 90 leading research institutions in the translational field located in 13 countries across Europe. EATRIS also supports the validation and development of novel tools for precision medicine and translational research in drug development. By providing access to accredited facilities as well as market-oriented expertise, including innovation management, regulatory and health-technology assessment, your validation needs are covered in a one-stop shop.
Why work with us
FR, NL, CZ, SE, NO, FI, IT, ES, SI, LU, LV, PO, BG
EATRIS, the European infrastructure for translational medicine, provides high quality services in early development of novel therapeutics and diagnostics. Translational research is defined as research that develops promising biomedical innovations 'from bench to bedside,' and conversely brings clinical insights from bedside back to bench.
Translational research is a highly multi-disciplinary and complex undertaking. As a consequence, a major challenge in developing new innovations is understanding what steps need to be taken, and what expertise and technologies are suitable to perform these steps. External researchers in need for academic support will find that EATRIS is able to provide guidance by means of regulatory, clinical and technological expertise available within the infrastructure. Subsequently, EATRIS will match the need with the capabilities within the infrastructure and facilitate collaboration among academics and between academics and companies.
Biomedical inventions frequently fail to pass the “valley of death” for various reasons. EATRIS aims to overcome translational challenges by (1) developing new enabling technologies within the consortium, and (2) making high quality services available for other researchers.
EATRIS strives to accelerate medicines and diagnostics development by utilising cutting-edge, enabling technologies in early translational research. Academic researchers, companies and charities can access clinical expertise and high-end facilities that are available within the 80 top-tier academic centres across Europe comprising EATRIS. Member institutions are selected on the basis of their track record in public-private collaboration in translational development and their multidisciplinary teams of leading academic experts, high-end research facilities, production laboratories and licenses.
We focus on preclinical and early clinical development of drugs, vaccines and diagnostics. Solutions are provided in the fields of advanced therapy medicinal products, biomarkers, imaging and tracing, small molecules and vaccines.
The wide-ranging services portfolio focuses on supporting early decision-making and de-risking of projects. Examples include validation and development of in vitro and in vivo biomarkers for patient stratification, molecular imaging tracers for drug development programmes, GMP manufacturing of cellular therapy products, patient-derived xenograft models, and many more highly specialised capabilities.
ECRIN is a pan-European distributed infrastructure that links scientific partners across Europe to facilitate multinational clinical research. ECRIN provides sponsors and investigators with support for the development and implementation of multinational clinical trials.
Why work with us
FR, DE, HU, IT, NO, ES, PT, CZ, IE
Observer: CH, SK, PL
Since its creation in 2004, ECRIN has been working to help researchers overcome the challenges inherent to multinational clinical trials in Europe.
ECRIN focuses on academic-sponsored multinational clinical trials as well as clinical trials initiated by biotech and medical device small and medium enterprises (SMEs). It provides support to sponsors and investigator-initiated trials and helps them navigate Europe’s fragmented health and legal systems. Multi-country clinical trials mean greater access to patients, resources, and expertise, and, in turn, faster and potentially more robust results.
ECRIN’s organisational model is based on country membership. Each country has a European Correspondent, who manages the trial portfolio and coordinates with the national scientific hub (i.e. network of clinical trial units, CTUs) with support from the Paris-based Core Team.
ECRIN provides support for the preparation of multinational clinical trials (e.g. trial logistics, funding applications), the validation of study protocols (scientific and logistical review), and trial management (coordination, submissions to competent authorities and ethics committees; monitoring; adverse event reporting; data management). In support of these activities, it develops and maintains freely accessible tools such as databases on regulatory and ethical requirements, outcome measures, and risk-based monitoring.
ECRIN currently provides consultancy and management services to more than 40 trials, with an average of seven countries per trial.
In addition, ECRIN contributes to capacity building projects aiming to establish shared services in biomedical areas and to foster international cooperation in non-commercial trials.
Please note: Most of the RIs are constantly developing their portfolio of services, so if you do not find the service/tool you are looking for, do not hesitate to contact the RI and ask for it!